Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 13/20 | 0.45 |
| ▸ | GSK3B | P49841 | 9/20 | 0.45 |
| ▸ | FLT3 | P36888 | 6/20 | 0.44 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.41 |
| ▸ | CDK1 | P06493 | 3/20 | 0.41 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPKAPK2 | P49137 | 3/20 | 0.34 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.34 |
| ▸ | MAPKAPK3 | Q16644 | 1/20 | 0.34 |
| ▸ | KIT | P10721 | 3/20 | 0.34 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3019131 | 1.00 | CDK2 (0.45) | CDK2GSK3BFLT3CCNE1CHEK1 | |
| SCHEMBL3024616 | 1.00 | CDK2 (0.45) | CDK2GSK3BFLT3CCNE1CHEK1 | |
| SCHEMBL3530000 | 0.86 | CDK2 (0.53) | CDK2GSK3BFLT3CCNE1CHEK1 | |
| SCHEMBL3022717 | 0.86 | CDK2 (0.61) | CDK2GSK3BFLT3CCNE1CHEK1 | |
| SCHEMBL3526043 | 0.86 | CDK2 (0.61) | CDK2GSK3BFLT3CCNE1CHEK1 | |
| SCHEMBL3253433 | 0.86 | CDK2 (0.61) | CDK2GSK3BFLT3CCNE1CHEK1 | |
| SCHEMBL3025258 | 0.81 | CDK2 (0.47) | CDK2FLT3CCNE1CDK1MAPK8 | |
| SCHEMBL3025252 | 0.81 | CDK2 (0.47) | CDK2FLT3CCNE1CDK1MAPK8 | |
| SCHEMBL3023428 | 0.79 | SYK (0.49) | CDK2GSK3BFLT3CCNE1CHEK1 | |
| SCHEMBL3023426 | 0.79 | SYK (0.49) | CDK2GSK3BFLT3CCNE1CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2010-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100204212-A1 | FUSED HETEROCYCLIC COMPOUNDS USEFUL AS KINASE MODULATORS | MAP2K2, MAP3K2, MAP4K2 | CDK2 40/4885GSK3B 543/4885FLT3 345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.